Salicylamide

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

supporting study

Study period:

1946 or before

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: see 'Remark'

Remarks:

Study published in a peer-reviewed journal, according to scientific standards. Experimental details documented, but no data on acclimatization and housing. Results: Mortalities tabulated after 1 and 7 days, but no statistical determination of LD50. Performed 1946, before GLP and OECD guidelines were introduced. Sufficient numbers of animals investigated, but sex not stated.

Cross-reference

Reason / purpose for cross-reference:

reference to same study

Data source

Reference

Reference Type:

publication

Title:

Pharmacological and toxicological studies on salicylamide

Author:

Ichniowski CT & Hueper WC

Year:

1946

Bibliographic source:

J. Am. Pharm. Assoc. Sci. Ed. 35: 225-230

Materials and methods

Test guideline

Qualifier:

no guideline available

Principles of method if other than guideline:

Acute toxicity study with intraperitoneal application, otherwise similar to acute oral toxicity.

GLP compliance:

no

Remarks:

GLP not available at study time

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Salicylamide

EC Number:

200-609-3

EC Name:

Salicylamide

Cas Number:

65-45-2

Molecular formula:

C7H7NO2

IUPAC Name:

salicylamide

Details on test material:

- Substance type: Pure test substance
- Physical state: Solid; yellowish white crystalline powder
- Melting Point: 138°
- Taste: Practically tasteless

Test animals

Species:

rat

Strain:

not specified

Sex:

male/female

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: 0.5% gum tragacanth in water

Doses:

250, 500, 1000, and 1500 mg/kg body weight

No. of animals per sex per dose:

10 (sex not specified)

Control animals:

no

Details on study design:

- Duration of observation period following administration: 7 days
- Frequency of observations: 15, 30, 60, 90 min, 2, 3, 5, 24 h, daily until day 7; no weighing reported
- Necropsy of animals dying on test: yes
- Necropsy of survivors: not reported
- Other examinations performed: clinical signs

Statistics:

none

Results and discussion

Effect levels

Sex:

not specified

Dose descriptor:

LD50

Effect level:

> 500 - < 1 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: No statistical evaluation; mortalities 2/10 at 500 mg/kg bw; 9/10 at 1000 mg/kg bw

Mortality:

Mortalities 1/10 at 250 mg/kg bw; 2/10 at 500 mg/kg bw; 9/10 at 1000 mg/kg bw; 10/10 at 1500 mg/kg bw
All mortalities within 2 h after application, except for one animal in the lowest dose group, which was reported to be in good condition, and whose time and circumstances of death are not stated

Clinical signs:

Heavy depression (dose-dependent), hind leg paralysis
Recovery of survivors within 24 hours

Body weight:

no data

Gross pathology:

Congestion and hemorrhages of the lungs
Hyperemia of the meninges
All other organs grossly normal